Therapeutic drug monitoring market seen reaching $4.7 billion by 2033

Persistence Market Research projects steady growth for the global therapeutic drug monitoring market through 2033, driven by personalized medicine, chronic disease management, and broader use in hospitals and diagnostic labs. North America is expected to remain the largest regional market as healthcare systems invest in precision diagnostics.

Why it matters: - Therapeutic drug monitoring helps clinicians match drug doses to individual patients, which can improve treatment outcomes and reduce adverse effects. - The market’s growth reflects wider adoption of personalized medicine and the rising need to manage chronic diseases with complex medications.

What happened: - Persistence Market Research values the global therapeutic drug monitoring market at US$2.6 billion in 2026. - The firm projects the market will reach US$4.7 billion by 2033. - The forecast implies a CAGR of 8.9% from 2026 to 2033. - The report was released from Brenford, London, United Kingdom, on July 2, 2026. - The report offers a free sample at Want Market Insights? Get Your Free Report Sample. - The report also offers customization at Customize This Report for Your Exact Requirements. - The full report is available at Unlock Complete Insights – Buy the Full Report.

The details: - Drug assay products remain the leading product segment because of their clinical accuracy and broad use in dosage optimization. - Hospitals are the largest end-user segment because of high patient volumes and ongoing monitoring needs. - Diagnostic laboratories are gaining demand as providers outsource testing to improve efficiency. - North America is expected to remain the leading regional market because of advanced healthcare infrastructure, precision medicine adoption, and established diagnostics capacity. - Europe remains a significant market, supported by strong healthcare systems, personalized treatment adoption, and clinical research. - Asia Pacific is expected to grow as healthcare infrastructure improves, spending rises, and awareness of advanced diagnostics expands. - The market includes drug assay kits, analyzers, consumables, and related solutions. - Therapeutic drug monitoring technologies have improved test accuracy, reduced turnaround times, and strengthened laboratory workflows.

Between the lines: - The forecast points to a market that is shifting from niche testing to a broader tool for safer, more individualized care. - High equipment costs and specialized testing requirements could slow adoption in smaller or resource-constrained facilities. - A shortage of skilled laboratory professionals may also limit how quickly therapeutic drug monitoring expands. - Regional differences in healthcare infrastructure will likely shape how fast the market reaches patients outside major hospital systems.

What's next: - Expansion is likely to follow continued investment in laboratory diagnostics and clinical awareness around medication safety. - Market participants are likely to benefit most where hospitals, diagnostic labs, and precision medicine programs keep expanding. - Key players in the market include Abbott Laboratories, F. Hoffmann-La Roche Ltd., Siemens Healthineers, Thermo Fisher Scientific Inc., Danaher Corporation, Bio-Rad Laboratories, Randox Laboratories Ltd., BioMérieux SA, Sekisui Medical Co., Ltd., and ARK Diagnostics, Inc.